New hope for Tough-to-Treat pancreatic cancer?
NCT ID NCT07175389
Summary
This early-stage trial is testing the safety and effectiveness of a new two-drug combination (JDB153 and serplulimab) for people with advanced pancreatic cancer that has stopped responding to standard treatments. It will enroll about 10 patients to see if the treatment can shrink tumors and how well it is tolerated. The goal is to find a new option to control this difficult disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.